Vermillion Posts 6 Percent Rise in Q2 Revenues, Halts OVA2 Development | GenomeWeb

This story originally ran on Aug. 16.

Vermillion this week reported $321,000 in revenues for the second quarter of 2012, up 6 percent from $304,000 in same period last year.

The rise was driven by an increase in sales of the company's OVA1 ovarian cancer diagnostic. Test volume for OVA1 was 4,150 during the quarter, up 6 percent compared to Q2 2011 and in line with the company's forecast.

Vermillion's license revenues, collected through its agreement with Quest Diagnostics, were flat year over year at $113,000.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Science this week: experts say race is not a sufficient proxy for studying human genetic diversity and more.

Technology Review writes that CRISPR/Cas9 gene editing firm Editas' success may hinge on a patent case.

Researchers unearthed a bioinformatics error in the Science paper reporting the first ancient African genome, and the authors are seeking an erratum.

A boy's cystic fibrosis carrier status was revealed by a teacher to the parents of children with CF who then sought the boy's transfer to another school, leading to a lawsuit.